{"gene":"GPNMB","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2007,"finding":"GPNMB translocates from the Golgi apparatus to peripheral vesicular compartments upon macrophage activation with IFN-γ and LPS. Overexpression reduces IL-6, IL-12p40, and NO production in response to LPS, establishing GPNMB as a negative regulator of macrophage inflammatory responses.","method":"Epitope-tagged GPNMB overexpression in RAW264.7 cells, fluorescence microscopy co-localization with Golgi marker (coat protein beta), cytokine/NO measurement; DBA/2J mice with inactivating Gpnmb mutation as loss-of-function model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain- and loss-of-function (overexpression + natural mutant mouse), multiple orthogonal readouts (localization, cytokine levels, NO), replicated in cell and in vivo models","pmids":["17475886"],"is_preprint":false},{"year":2009,"finding":"GPNMB localizes predominantly to melanosomes (and to a lesser degree lysosomes) in melanocytes, with lesser surface expression. Keratinocytes adhere to immobilized GPNMB in an RGD-dependent manner, establishing GPNMB as a melanosome-associated glycoprotein mediating melanocyte–keratinocyte adhesion via its RGD motif.","method":"Immunofluorescence, subcellular fractionation, newly developed monoclonal antibody for surface staining, RGD-dependent adhesion assay with PAM212 keratinocytes","journal":"Experimental dermatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence (adhesion assay), RGD-blocking control, multiple cell types tested","pmids":["19320736"],"is_preprint":false},{"year":2002,"finding":"EGFP-tagged GPNMB localizes to vesicular, endosomal-like structures in non-pigmented COS7 and HEK293 cells, consistent with an endosomal/melanosomal sorting signal (ExxPLL di-leucine motif) in its cytoplasmic domain.","method":"EGFP-GPNMB transfection in COS7 and HEK293 cells with fluorescence microscopy; sequence analysis identifying ExxPLL motif","journal":"Brain research. Gene expression patterns","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization in two cell lines, but no functional mutagenesis of the sorting motif in this study","pmids":["12638126"],"is_preprint":false},{"year":2008,"finding":"Gpnmb expression in melanoblasts is directly regulated by the transcription factor MITF. A conserved element (GPNMB-MCS3) containing two MITF consensus binding sites drives Gpnmb expression in melanoblasts in vivo; deletion of the 5'-most MITF site dramatically reduces enhancer activity.","method":"Luciferase reporter assay in melanocytes, in vivo enhancer-driven expression in melanoblasts, MITF mutant mouse analysis, whole-genome annotation of MITF binding sites","journal":"Pigment cell & melanoma research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reporter assay with deletion mutagenesis plus in vivo validation in mutant animals; multiple orthogonal approaches","pmids":["18983539"],"is_preprint":false},{"year":2012,"finding":"Silencing GPNMB by siRNA in PIG1 melanocytes sharply reduces the total number of melanosomes and decreases expression of melanosome structural proteins (tyrosinase, TRP1, Pmel17/gp100, OA1), demonstrating that GPNMB is required for melanosome formation in a MITF-independent fashion.","method":"siRNA knockdown of GPNMB in PIG1 melanocytes; transmission electron microscopy, qPCR, Western blot, immunofluorescence","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function with TEM as direct ultrastructural readout plus multiple molecular markers; single lab but ≥2 orthogonal methods","pmids":["22912767"],"is_preprint":false},{"year":2013,"finding":"The PKD domain of GPNMB lacks the sorting function present in the homologous PKD domain of PMEL. The difference is attributed to extensive N-glycosylation of the GPNMB PKD domain, which nullifies its sorting function. As a result, GPNMB localizes to compartments distinct from PMEL-containing multivesicular premelanosomes and is absent from amyloid fibrils.","method":"Domain-swapping experiments between PMEL and GPNMB in melanocytes and HeLa cells; fluorescence microscopy; glycosylation analysis","journal":"Pigment cell & melanoma research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — domain-swap mutagenesis plus localization in two cell types; mechanistic attribution to N-glycosylation of PKD domain","pmids":["23452376"],"is_preprint":false},{"year":2013,"finding":"ET-1 induces melanogenesis via a MITF-regulated GPNMB pathway: ET-1 upregulates MITF, which in turn increases GPNMB expression; GPNMB silencing abolishes ET-1-induced melanosome formation and melanin synthesis, and MITF siRNA suppresses GPNMB expression and prevents ET-1-mediated pigmentation.","method":"siRNA knockdown of GPNMB and MITF in melanocytes, melanin quantification, melanosome counting, Western blot","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistatic placement of MITF upstream of GPNMB by dual siRNA knockdown; single lab","pmids":["23884103"],"is_preprint":false},{"year":2015,"finding":"GPNMB engages α5β1 integrin through its RGD motif to promote breast cancer cell adhesion to fibronectin and activate Src and FAK signaling. Both the RGD motif and cytoplasmic tail are required for primary tumor growth, but only the RGD motif is required for lung metastasis. GPNMB also increases NRP-1 expression to potentiate VEGF signaling required for tumor growth but not metastasis.","method":"RGD-motif mutagenesis, cytoplasmic tail deletion, integrin co-immunoprecipitation, in vivo breast cancer mouse models, RNAseq correlation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-directed mutagenesis of RGD and cytoplasmic tail with in vitro and in vivo functional rescue; Co-IP; multiple orthogonal approaches","pmids":["25772243"],"is_preprint":false},{"year":2016,"finding":"M2 macrophage-secreted GPNMB promotes MSC survival, proliferation, and migration via CD44 receptor, activating ERK and AKT signaling pathways in MSCs. Loss-of-function and rescue experiments confirmed CD44-dependence.","method":"Loss-of-function (GPNMB knockdown) and rescue studies in macrophage–MSC co-culture system; ERK/AKT phosphorylation assays; CD44 blocking","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function plus rescue, downstream signaling readout; single lab","pmids":["26442636"],"is_preprint":false},{"year":2016,"finding":"GPNMB transgenic overexpression in mice enhances bone formation, increases osteoblast numbers and bone formation rates, and is associated with upregulated TGF-β1 and TGF-β receptor I/II expression in osteoblasts, indicating an osteoinductive effect.","method":"Transgenic mouse (CMV-promoter GPNMB overexpression): micro-CT, histomorphometry, biomechanical testing, ELISA, qRT-PCR","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain-of-function with multiple structural and molecular readouts; single lab","pmids":["25899717"],"is_preprint":false},{"year":2016,"finding":"GPNMB interacts with Na+/K+-ATPase α subunits to activate PI3K/Akt and MEK/ERK pathways in glioblastoma. Ouabain (a Na+/K+-ATPase inhibitor) suppresses GPNMB-driven glioma growth and blocks GPNMB-induced glioma cell migration. This interaction was confirmed in both a murine glioma model and human glioblastoma tumors.","method":"Co-immunoprecipitation (GPNMB–Na+/K+-ATPase), transgenic GPNMB mice with in vivo glioma implantation, ouabain pharmacological inhibition, migration assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vivo functional validation with pharmacological inhibition; single lab","pmids":["27836549"],"is_preprint":false},{"year":2016,"finding":"Recombinant GPNMB protects motor neurons from mutant TDP-43-induced cell death by activating ERK1/2 and Akt signaling pathways. GPNMB co-localizes with TDP-43 aggregates in neurons (but not astrocytes or microglia) of ALS patient spinal cord.","method":"Recombinant GPNMB treatment of NSC34 motor neuron cells transfected with mutant TDP-43; Western blot for p-ERK1/2, p-Akt; immunohistochemistry of ALS patient spinal cord","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant protein rescue experiment with defined signaling readout; single lab","pmids":["27935101"],"is_preprint":false},{"year":2017,"finding":"GPNMB neuroprotection during ischemia-reperfusion involves activation of ERK1/2 and Akt. Transgenic GPNMB overexpression significantly reduces infarct volume and increases phospho-ERK1/2 and phospho-Akt. Recombinant extracellular GPNMB fragment alone is sufficient to reduce infarction, mapping the neuroprotective activity to the extracellular domain.","method":"GPNMB transgenic mice with MCAO model; recombinant GPNMB treatment; Western blot for p-ERK1/2 and p-Akt; infarct volume measurement","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression plus recombinant protein rescue, signaling pathway readout; single lab","pmids":["25010402"],"is_preprint":false},{"year":2017,"finding":"GPNMB induces BiP (GRP78) expression during ER stress by translocating to the nucleus and promoting BiP pre-mRNA splicing through a mechanism independent of the three canonical UPR transducers (IRE1, PERK, ATF6). GPNMB transgenic mice exhibit elevated BiP and reduced infarct size after cerebral artery occlusion.","method":"Thapsigargin-induced ER stress, nuclear fractionation showing GPNMB nuclear translocation, BiP mRNA/pre-mRNA splicing assay, IRE1/PERK/ATF6 pathway inhibitor controls, GPNMB transgenic mouse MCAO model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — nuclear translocation by fractionation, mRNA splicing assay, pathway exclusion controls, in vivo validation; multiple orthogonal methods in one study","pmids":["28939899"],"is_preprint":false},{"year":2018,"finding":"The anti-inflammatory effects of soluble GPNMB on astrocytes are mediated through the CD44 receptor. Recombinant GPNMB attenuates cytokine-induced iNOS, NO, ROS, and IL-6 in astrocytes; this effect is lost in CD44 knockout astrocytes.","method":"Recombinant GPNMB treatment of wild-type and CD44-KO primary mouse astrocytes; measurement of iNOS, NO, ROS, IL-6","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO of receptor (CD44-KO astrocytes) as clean loss-of-function; multiple inflammatory readouts; confirms CD44 as functional receptor","pmids":["29519253"],"is_preprint":false},{"year":2019,"finding":"Soluble macrophage-derived GPNMB activates cancer cells to express IL-33 and its receptor IL-1RL1 through the CD44 receptor, driving cancer stem cell formation (spheroids), prolonged survival, and metastatic phenotype. IL-33 binding to IL-1RL1 is sufficient to induce tumor spheroid formation.","method":"Mouse tumor models with Gpnmb-mutant DBA/2J mice, GPNMB receptor blocking with anti-CD44, IL-33/IL-1RL1 functional reconstitution, spheroid formation assay","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model, receptor blocking, reconstitution with IL-33; multiple orthogonal approaches establishing GPNMB→CD44→IL-33 axis","pmids":["32728200"],"is_preprint":false},{"year":2019,"finding":"Gpnmb is a liver-secreted factor that stimulates lipogenesis in white adipose tissue (WAT). Hepatic SREBP pathway inhibition increases Gpnmb transcription and promotes its processing to a secreted form. Liver-specific knockdown or neutralizing antibody against Gpnmb improves metabolic parameters and promotes WAT beiging.","method":"Liver-specific Gpnmb knockdown, neutralizing antibody treatment, Gpnmb transgenic mice, SREBP pathway manipulation, metabolic phenotyping (weight, insulin sensitivity)","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — liver-specific KD, neutralizing antibody, transgenic overexpression, multiple metabolic readouts; replicated across multiple genetic and pharmacological approaches","pmids":["32694855"],"is_preprint":false},{"year":2019,"finding":"GPNMB is a direct transcriptional target of TFE3 fusion proteins. In a TFE3-RCC mouse model, GPNMB expression was elevated in TFE3-driven renal tumors, and TFE3 fusion was confirmed to directly transactivate GPNMB.","method":"PRCC-TFE3 transgenic mouse model; GPNMB IHC; confirmed TFE3 direct transcriptional target by reporter/functional analysis","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic model with transcriptional target confirmation; single lab","pmids":["31043488"],"is_preprint":false},{"year":2019,"finding":"GPNMB upregulation is downstream of TSC2 loss and is dependent on MiT/TFE transcription factors and mTORC1 activity. In AML/kidney cell lines with CRISPR-mediated TSC2 loss, GPNMB is upregulated in a TFE3/TFEB- and mTORC1-dependent fashion.","method":"CRISPR-Cas9 TSC2/TFE3/TFEB knockout in AML and kidney cell lines; GPNMB immunohistochemistry; Tsc2+/- mouse model","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR genetic dissection in multiple cell lines plus in vivo mouse model, pathway placed downstream of TSC2/mTORC1/MiT-TFE axis","pmids":["35072947"],"is_preprint":false},{"year":2019,"finding":"GPNMB regulates EGFR activation and downstream STAT3 signaling in NSCLC. N-glycosylation at Asn134 of GPNMB is essential for its binding to the C-terminus of mutated EGFR and for ligand-independent EGFR phosphorylation at Y845. Depleting N134 glycosylation abolishes GPNMB–EGFR binding and downstream signaling.","method":"Membrane proteomics, Co-IP of GPNMB–EGFR, N134A glycosylation mutant, phospho-EGFR (Y845) and STAT3 assays, in vivo metastasis model","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of glycosylation site, Co-IP, in vitro signaling assay, in vivo validation; multiple orthogonal methods","pmids":["33706413"],"is_preprint":false},{"year":2019,"finding":"The Takayasu arteritis risk allele in IL6 (rs2069837 A) represses GPNMB expression ~520 kb away by recruiting a MEF2-HDAC repressive complex through long-range intrachromatin looping. HDAC inhibition reverses GPNMB suppression in macrophages from AA genotype individuals.","method":"EMSA, DNA affinity precipitation + mass spectrometry, luciferase reporter assay, chromosome conformation capture (3C), primary macrophage experiments with HDAC inhibition","journal":"Annals of the rheumatic diseases","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — 3C for chromatin looping, EMSA and affinity pulldown for protein-DNA interaction, reporter assay with deletion, pharmacological reversal; multiple orthogonal Tier 1-2 methods","pmids":["31315839"],"is_preprint":false},{"year":2021,"finding":"GPNMB reduces macrophage inflammatory capacity by inhibiting NF-κB signaling largely through binding to CD44. In GPNMB-KO mice, macrophages produce more inflammatory cytokines; supplementation with recombinant soluble GPNMB extracellular domain abolishes this difference. Macrophage depletion abrogates the worsened metabolic phenotype of GPNMB-KO mice.","method":"GPNMB-KO mouse (CRISPR), HFD metabolic phenotyping, macrophage isolation and cytokine measurement, recombinant GPNMB rescue, clodronate liposome macrophage depletion, NF-κB signaling assay, CD44 blocking","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with multiple orthogonal approaches: recombinant rescue, macrophage depletion, CD44 blocking, NF-κB readout","pmids":["34582891"],"is_preprint":false},{"year":2021,"finding":"Gpnmb is required for normal macrophage lysosome function. Gpnmb is the causal gene at the strongest QTL for lysosome function (Mlfm1). siRNA knockdown of Gpnmb in AKR/J macrophages and CRISPR-Cas9 deletion in RAW264.7 cells both decrease lysosome function; restoration of wild-type Gpnmb in a DBA/2 substrain recovers lysosome function.","method":"QTL mapping, siRNA knockdown, CRISPR-Cas9 knockout in RAW264.7 cells, dual-labeled lysosome function assay, DBA/2J-Gpnmb+/SjJ substrain comparison","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — three independent loss-of-function approaches (siRNA, CRISPR, natural null mutation) plus genetic rescue substrain; converging on lysosome function","pmids":["33986446"],"is_preprint":false},{"year":2021,"finding":"GPNMB reduces Aβ deposition and improves Alzheimer's-like behaviors in APP/PS1 mice by enhancing autophagy through suppression of mTOR signaling. Autophagy inhibitor 3-MA abolishes the beneficial effect of GPNMB on Aβ clearance, placing GPNMB upstream of mTOR-dependent autophagy.","method":"GPNMB overexpression in APP/PS1 mice; TEM and immunofluorescence for autophagy (beclin-1); 3-MA autophagy inhibition; Aβ quantification; mTOR pathway Western blot","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function plus pharmacological pathway blockade; single lab","pmids":["34695452"],"is_preprint":false},{"year":2022,"finding":"GPNMB co-immunoprecipitates and co-localizes with α-synuclein (aSyn) in cells. In iPSC-derived neurons, loss of GPNMB results in loss of ability to internalize aSyn fibrils and develop aSyn pathology.","method":"Co-immunoprecipitation, co-localization immunofluorescence, GPNMB loss-of-function in iPSC-derived neurons with aSyn fibril uptake assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus genetic loss-of-function in physiologically relevant iPSC-derived neurons with functional readout (fibril internalization)","pmids":["35981040"],"is_preprint":false},{"year":2022,"finding":"GPNMB binds to integrin αVβ1 receptor on adventitial fibroblasts and activates downstream Akt and Erk signaling, promoting extracellular matrix production. This was established by Co-IP, siRNA, and inhibitor intervention studies in Takayasu arteritis vascular fibrosis.","method":"Co-IP assay (GPNMB–integrin αVβ1), siRNA knockdown of integrin αVβ1, pharmacological pathway inhibitors (Akt/Erk), ECM gene expression assays in adventitial fibroblasts","journal":"Translational research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus siRNA and inhibitor validation; single lab","pmids":["36566014"],"is_preprint":false},{"year":2022,"finding":"HSP90 inhibition increases GPNMB cell-surface localization by inducing lysosomal dispersion toward the cell periphery and lysosome–plasma membrane fusion, delivering GPNMB to the cell surface. This is distinct from transcriptional induction and requires lysosomal repositioning.","method":"FACS-based genetic screen, live-cell imaging of lysosomal positioning, lysosome–plasma membrane fusion assay, GPNMB surface FACS after HSP90 inhibitor treatment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic screen plus mechanistic imaging of lysosomal dispersion; multiple orthogonal methods establishing lysosome-to-surface trafficking mechanism","pmids":["35110681"],"is_preprint":false},{"year":2023,"finding":"Macrophage-derived GPNMB is trapped by fibrotic ECM and activates resident fibroblasts via the CD44/Serpinb2 pathway, driving pulmonary fibrosis progression. Neutralizing antibodies against GPNMB or macrophage depletion attenuates fibroblast activation in fibrotic ECM.","method":"Silica-instilled mouse PF model, fibroblast activation assay with fibrotic ECM, GPNMB-neutralizing antibody treatment, macrophage depletion, Western blot for CD44/Serpinb2","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blockade and macrophage depletion with pathway readout; single lab","pmids":["36732560"],"is_preprint":false},{"year":2023,"finding":"Lactic acid-induced M2-like macrophage-derived GPNMB promotes OSCC cell migration, invasion, and EMT by binding to the CD44 receptor and activating the PI3K/AKT/mTOR signaling cascade. CD44 silencing abrogates these tumor-promoting effects.","method":"Co-culture system, GPNMB-CD44 binding assay, CD44 siRNA knockdown, PI3K/AKT/mTOR inhibition, migration/invasion assays","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor knockdown with pathway readout; single lab","pmids":["37806107"],"is_preprint":false},{"year":2024,"finding":"Bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts after myocardial infarction. GPNMB deficiency leads to increased mortality, cardiac rupture, and left ventricular dysfunction. GPR39 is identified as a receptor for circulating GPNMB; GPR39 absence negates the beneficial cardiac effects of GPNMB. Single-cell transcriptomics showed GPNMB enhances cardiomyocyte contraction and reduces fibroblast activation.","method":"Lineage tracing, bone-marrow transplantation, GPNMB loss-of-function (genetic), viral GPNMB delivery for gain-of-function, single-cell RNA sequencing, GPR39 KO rescue experiment","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO, KO rescue with GPR39-KO, viral delivery), lineage tracing, scRNA-seq; multiple orthogonal approaches identifying GPR39 as functional receptor","pmids":["39455836"],"is_preprint":false},{"year":2025,"finding":"GPNMB interacts with lysosomal vacuolar-type proton ATPase catalytic subunit A (ATP6V1A) to mediate microglial phagocytosis of pathological particles including neuronal debris and β-amyloid. GPNMB is internalized into cells, wraps engulfed particles, and presents them to lysosomes via ATP6V1A interaction. Activating ATP6V1A rescues GPNMB-deficiency-caused phagocytosis impairment.","method":"Co-immunoprecipitation (GPNMB–ATP6V1A), GPNMB genetic ablation, phagocytosis assay (engulfment and degradation), ATP6V1A activation rescue experiment, live-cell imaging of GPNMB trafficking","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifying interactor, KO phenotype, pharmacological rescue of phagocytosis; multiple orthogonal approaches","pmids":["39992792"],"is_preprint":false},{"year":2025,"finding":"PPARγ directly targets GPNMB to promote oligodendrocyte precursor cell (OPC) differentiation and CNS remyelination. PPARγ agonists increase GPNMB expression and enhance remyelination; oligodendrocyte-specific PPARγ KO decreases OPC maturation. GPNMB itself drives OPC-to-oligodendrocyte differentiation and promotes myelinogenesis.","method":"PPARγ oligodendrocyte-specific KO, PPARγ agonist treatment, ChIP/transcriptional target validation of GPNMB, cuprizone and lysophosphatidylcholine demyelination models, GPNMB overexpression/knockdown in OPCs","journal":"Brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-specific KO, direct transcriptional target confirmation, two independent demyelination models, GPNMB gain/loss-of-function; multiple orthogonal methods","pmids":["39756479"],"is_preprint":false},{"year":2012,"finding":"Glycosylation of GPNMB is inhibited by interaction with mutant SOD1(G93A) in NSC34 cells, increasing motor neuron vulnerability. Extracellular fragments of GPNMB secreted from activated astrocytes attenuate SOD1(G93A) neurotoxicity in neural cells, establishing a neuroprotective paracrine role.","method":"Co-culture of NSC34 cells and astrocytes, glycosylation assay, SOD1(G93A) interaction, neurotoxicity rescue with extracellular GPNMB fragments","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction and functional rescue; single lab, single study","pmids":["22891158"],"is_preprint":false},{"year":2015,"finding":"Soluble Gpnmb in NAFLD interacts with calnexin in hepatic macrophages and stellate cells, and this interaction is associated with reduced oxidative stress. Gpnmb transgenic overexpression ameliorates fat accumulation and liver fibrosis in diet-induced obesity.","method":"Gpnmb transgenic mice (aP2-driven), co-immunoprecipitation (Gpnmb–calnexin), oxidative stress markers, histological analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying calnexin interaction plus in vivo transgenic model; single lab","pmids":["26581806"],"is_preprint":false},{"year":2017,"finding":"p53 cooperates with cytokine-mediated transcription factors to regulate HGFIN/GPNMB expression. EMSA demonstrated that p53 can interact with HGFIN promoter fragments containing p53 consensus sites. Reporter gene analyses showed p53 level correlates with HGFIN promoter activity; the untranslated exon 1 acts as a negative regulator of upstream enhancing effects.","method":"EMSA with Cy3-labeled PCR fragments, luciferase reporter assays in cells with varying p53 levels, modified cell lines with reduced cytokine production","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and reporter assay with multiple cell lines; single lab, focused on promoter regulation","pmids":["15684612"],"is_preprint":false},{"year":2021,"finding":"Soluble DC-HIL (GPNMB) binds syndecan-4 on both T cells and endothelial cells. In an allergic contact dermatitis model, sDC-HIL downregulates the allergic reaction by reducing transendothelial T-cell migration (but not neutrophil or mast cell migration). This requires syndecan-4 expression on both endothelial cells and T cells.","method":"Allergic contact dermatitis mouse model, intravital microscopy, syndecan-4-deficient mice, intravenous sDC-HIL infusion, flow cytometry of immune cell infiltration","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO of syndecan-4 in both cell types establishes receptor requirement; intravital microscopy confirms cell-specific migration block; multiple orthogonal methods","pmids":["34695414"],"is_preprint":false},{"year":2021,"finding":"GPNMB extracellular soluble fragment protects melanocytes from oxidative stress-induced cytotoxicity and melanogenesis impairment through suppression of AKT phosphorylation, independently of CD44 (CD44 knockdown did not affect the protective effect).","method":"siRNA knockdown of CD44, recombinant soluble GPNMB treatment, AKT/ERK/p38/JNK phosphorylation assays, melanocyte viability assay","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor knockdown plus signaling assays establishing CD44-independent, AKT-dependent mechanism; single lab","pmids":["34639184"],"is_preprint":false}],"current_model":"GPNMB is a type I transmembrane glycoprotein that functions as a context-dependent signaling molecule: it localizes to melanosomes/lysosomes via a cytoplasmic ExxPLL sorting motif and is required for melanosome biogenesis; its extracellular RGD domain mediates cell adhesion through integrins (α5β1, αVβ1) and activates Src/FAK and Akt/Erk signaling; its soluble ectodomain (shed by ADAM10) signals through CD44 to inhibit NF-κB-mediated inflammation and through GPR39 to support cardiac repair; it interacts with α-synuclein and is required for aSyn fibril internalization; it promotes lysosomal function by interacting with ATP6V1A to facilitate phagocytic degradation; it translocates to the nucleus during ER stress to enhance BiP pre-mRNA splicing; and its expression is transcriptionally regulated by MITF (in melanocytes), TFE3/TFEB (downstream of TSC/mTOR), PPARγ (in oligodendrocytes), and p53/cytokine-mediated transcription factors."},"narrative":{"mechanistic_narrative":"GPNMB is a type I transmembrane glycoprotein that operates both as a melanosomal/lysosomal sorting cargo and, after ectodomain shedding, as a secreted signaling ligand coordinating tissue repair, anti-inflammatory responses, and protein/particle degradation [PMID:19320736, PMID:32694855, PMID:34582891]. In melanocytes it localizes predominantly to melanosomes via a cytoplasmic ExxPLL di-leucine sorting motif and is required for melanosome biogenesis, acting downstream of MITF, whose direct binding to a conserved enhancer drives GPNMB transcription [PMID:12638126, PMID:18983539, PMID:22912767]. Distinct N-glycosylation of its PKD domain diverts GPNMB away from the PMEL amyloidogenic compartment, and its surface delivery can be controlled by lysosome-to-plasma-membrane repositioning [PMID:23452376, PMID:35110681]. The extracellular domain mediates adhesion and signaling through multiple receptors: an RGD motif engages integrins (α5β1, αVβ1) to activate Src/FAK and Akt/Erk and drive tumor growth and ECM production, while the shed soluble ectodomain signals through CD44 to inhibit NF-κB-dependent inflammation in macrophages and astrocytes and, through GPR39, to support cardiac repair after myocardial infarction [PMID:25772243, PMID:29519253, PMID:34582891, PMID:36566014, PMID:39455836]. Beyond cell-surface signaling, GPNMB promotes lysosomal and degradative function by interacting with the vacuolar ATPase subunit ATP6V1A to drive microglial phagocytosis of neuronal debris and β-amyloid, and it is required for internalization of α-synuclein fibrils through direct binding to α-synuclein [PMID:33986446, PMID:35981040, PMID:39992792]. During ER stress it translocates to the nucleus to enhance BiP pre-mRNA splicing independently of the canonical UPR transducers [PMID:28939899]. Its expression is integrated into multiple transcriptional programs, including MITF, the MiT/TFE factors TFE3/TFEB downstream of TSC2/mTORC1, PPARγ during oligodendrocyte differentiation, and p53/cytokine-driven regulation [PMID:18983539, PMID:35072947, PMID:39756479, PMID:15684612].","teleology":[{"year":2002,"claim":"Established that GPNMB carries an intrinsic endosomal/melanosomal sorting determinant, framing it as a vesicular trafficking cargo rather than a simple surface protein.","evidence":"EGFP-GPNMB localization in COS7 and HEK293 cells with identification of an ExxPLL di-leucine motif","pmids":["12638126"],"confidence":"Medium","gaps":["No functional mutagenesis of the sorting motif in this study","Sorting machinery (adaptors) not identified"]},{"year":2008,"claim":"Identified MITF as a direct upstream transcriptional driver of GPNMB in the melanocyte lineage, placing GPNMB within the pigmentation gene regulatory network.","evidence":"Luciferase reporter with MITF-site deletion plus in vivo enhancer activity and MITF mutant mouse analysis","pmids":["18983539"],"confidence":"High","gaps":["Did not address MITF-independent expression in other tissues","Did not link transcription to melanosome phenotype directly"]},{"year":2009,"claim":"Showed GPNMB is a melanosome-associated glycoprotein whose RGD motif mediates melanocyte-keratinocyte adhesion, giving the extracellular domain a defined adhesive function.","evidence":"Immunofluorescence, subcellular fractionation, and RGD-dependent keratinocyte adhesion assay","pmids":["19320736"],"confidence":"High","gaps":["Adhesion receptor on keratinocytes not identified in this study","Functional significance for melanosome transfer not tested"]},{"year":2012,"claim":"Demonstrated GPNMB is required for melanosome biogenesis, establishing a cell-intrinsic structural/biogenic role distinct from its signaling functions.","evidence":"siRNA knockdown in PIG1 melanocytes with TEM, qPCR, and Western blot for melanosome markers","pmids":["22912767"],"confidence":"High","gaps":["Mechanism by which GPNMB supports melanosome formation not resolved","Whether effect is via sorting of structural proteins unknown"]},{"year":2007,"claim":"First established GPNMB as a negative regulator of macrophage inflammation, reframing it from a structural pigment-cell protein to an immunomodulator.","evidence":"Overexpression in RAW264.7 cells with cytokine/NO readouts plus DBA/2J Gpnmb-mutant mouse","pmids":["17475886"],"confidence":"High","gaps":["Receptor mediating anti-inflammatory effect not identified","Mechanism linking localization shift to cytokine suppression unclear"]},{"year":2013,"claim":"Explained why GPNMB diverges from its PMEL paralog by attributing loss of PKD-domain sorting to N-glycosylation, separating GPNMB from the amyloidogenic premelanosome compartment.","evidence":"PMEL/GPNMB domain-swap mutagenesis with glycosylation analysis and localization in melanocytes and HeLa cells","pmids":["23452376"],"confidence":"High","gaps":["Functional consequence of compartment segregation not tested","ET-1/MITF axis (idx 6) link to sorting not addressed"]},{"year":2015,"claim":"Mapped tumor-promoting functions to distinct GPNMB domains, showing RGD-integrin engagement drives metastasis while both RGD and cytoplasmic tail support primary growth via Src/FAK.","evidence":"RGD and cytoplasmic-tail mutagenesis, integrin Co-IP, and in vivo breast cancer mouse models","pmids":["25772243"],"confidence":"High","gaps":["Cytoplasmic tail downstream effectors not defined","How NRP-1 upregulation occurs mechanistically unclear"]},{"year":2016,"claim":"Defined CD44 as a functional receptor for soluble GPNMB driving ERK/AKT-mediated survival and migration, and extended GPNMB signaling to additional receptors (Na+/K+-ATPase) and tissues (bone).","evidence":"Macrophage-MSC co-culture with CD44 blocking and rescue; Co-IP with Na+/K+-ATPase in glioma; transgenic bone-formation phenotyping","pmids":["26442636","27836549","25899717"],"confidence":"Medium","gaps":["Whether single ligand engages multiple receptors simultaneously unknown","Stoichiometry and affinity of receptor interactions not measured"]},{"year":2017,"claim":"Uncovered a non-canonical nuclear function in which GPNMB enhances BiP pre-mRNA splicing during ER stress, independent of IRE1/PERK/ATF6, linking GPNMB to UPR and neuroprotection.","evidence":"Thapsigargin ER stress with nuclear fractionation, BiP splicing assay, UPR-pathway inhibitor controls, and transgenic MCAO mice","pmids":["28939899"],"confidence":"High","gaps":["How a transmembrane protein reaches the nucleus mechanistically unresolved","Splicing machinery partners not identified"]},{"year":2018,"claim":"Confirmed CD44 as the receptor for the anti-inflammatory action of soluble GPNMB using clean genetic loss-of-function, generalizing this axis to CNS glia.","evidence":"Recombinant GPNMB on wild-type vs CD44-KO astrocytes with iNOS/NO/ROS/IL-6 readouts","pmids":["29519253"],"confidence":"High","gaps":["Downstream NF-κB step not yet directly tied in this study","Co-receptors of CD44 not examined"]},{"year":2019,"claim":"Integrated GPNMB into multiple transcriptional and metabolic programs—MiT/TFE downstream of TSC2/mTORC1, TFE3 fusions in RCC, hepatic SREBP-controlled secretion driving adipose lipogenesis, and EGFR-glycosylation-dependent signaling in NSCLC.","evidence":"CRISPR TSC2/TFE3/TFEB knockouts; PRCC-TFE3 transgenic model; liver-specific knockdown/neutralizing antibody with metabolic phenotyping; N134A glycosylation mutant with EGFR Co-IP","pmids":["35072947","31043488","32694855","33706413"],"confidence":"High","gaps":["Tissue-specific balance between secreted ligand and surface signaling unclear","Whether EGFR and integrin functions share a common pool of GPNMB unknown"]},{"year":2019,"claim":"Showed long-range chromatin regulation of GPNMB, with a Takayasu-associated IL6 variant recruiting a MEF2-HDAC repressive complex to suppress GPNMB ~520 kb away.","evidence":"EMSA, DNA affinity precipitation/MS, luciferase reporters, 3C chromatin looping, and HDAC inhibition in primary macrophages","pmids":["31315839"],"confidence":"High","gaps":["Functional consequence of macrophage GPNMB loss in disease not fully traced here","Other distal regulatory elements not catalogued"]},{"year":2021,"claim":"Established GPNMB as a determinant of macrophage lysosome function and confirmed CD44-dependent suppression of NF-κB inflammation, tying a degradative-organelle role to metabolic and immune phenotypes.","evidence":"QTL mapping with siRNA, CRISPR-KO, and natural-null rescue for lysosome function; GPNMB-KO mouse HFD model with recombinant rescue, macrophage depletion, CD44 blocking, and NF-κB readout","pmids":["33986446","34582891"],"confidence":"High","gaps":["Molecular link between GPNMB and lysosome machinery not yet defined in these studies","Relationship between surface signaling and intracellular lysosomal role unresolved"]},{"year":2022,"claim":"Identified GPNMB as a direct α-synuclein interactor required for fibril internalization and as an integrin αVβ1 ligand driving fibrosis, expanding its roles into neurodegeneration uptake and pathological ECM production.","evidence":"Co-IP and co-localization with α-synuclein plus iPSC-neuron loss-of-function fibril-uptake assay; Co-IP, siRNA, and inhibitor studies for αVβ1 in fibroblasts","pmids":["35981040","36566014"],"confidence":"High","gaps":["Whether GPNMB acts as a fibril receptor or co-factor not fully defined","Mechanism coupling fibril binding to internalization route unknown"]},{"year":2024,"claim":"Identified GPR39 as a receptor for circulating GPNMB mediating cardiac repair, and resolved the cell-of-origin (bone-marrow-derived macrophages) for injury-induced GPNMB.","evidence":"Lineage tracing, bone-marrow transplantation, genetic loss-of-function, viral gain-of-function, scRNA-seq, and GPR39-KO rescue in myocardial infarction","pmids":["39455836"],"confidence":"High","gaps":["GPR39 vs CD44 receptor selection by tissue not explained","Direct GPNMB-GPR39 binding interface not mapped"]},{"year":2025,"claim":"Defined a mechanistic link between GPNMB and the degradative apparatus, showing GPNMB binds the V-ATPase subunit ATP6V1A to present engulfed particles to lysosomes during microglial phagocytosis, and connected GPNMB to PPARγ-driven remyelination.","evidence":"Co-IP of GPNMB-ATP6V1A with KO phagocytosis assay and ATP6V1A activation rescue; PPARγ oligodendrocyte-specific KO, ChIP target validation, and demyelination models","pmids":["39992792","39756479"],"confidence":"High","gaps":["How GPNMB couples particle wrapping to V-ATPase function structurally unknown","Whether ATP6V1A interaction underlies earlier lysosome-function QTL effect not directly tested"]},{"year":null,"claim":"It remains unresolved how GPNMB partitions among its diverse receptors (CD44, GPR39, integrins α5β1/αVβ1, syndecan-4) and intracellular partners (ATP6V1A, α-synuclein, calnexin) in a tissue- and context-specific manner, and what governs the choice between membrane signaling, ectodomain shedding, and nuclear translocation.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying model linking receptor selection to ligand processing","Structural basis of multi-receptor engagement undefined","Relative in vivo contribution of each axis to physiology not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[1,7]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[14,21,29]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,14,25,29]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[1,22,26,30]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,7,26]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[12,14,16,21]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,14,25,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,14,21]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[23,30]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,33]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,18,20,31,34]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[4,22]}],"complexes":[],"partners":["CD44","GPR39","ITGAV","ITGB1","ATP6V1A","SNCA","EGFR","SDC4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14956","full_name":"Transmembrane glycoprotein NMB","aliases":["Hematopoietic growth factor inducible neurokinin-1 type"],"length_aa":572,"mass_kda":63.9,"function":"Could be a melanogenic enzyme","subcellular_location":"Cell membrane; Melanosome membrane; Early endosome membrane","url":"https://www.uniprot.org/uniprotkb/Q14956/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPNMB","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPNMB","total_profiled":1310},"omim":[{"mim_id":"617920","title":"AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3; PLCA3","url":"https://www.omim.org/entry/617920"},{"mim_id":"604368","title":"GLYCOPROTEIN NMB; GPNMB","url":"https://www.omim.org/entry/604368"},{"mim_id":"600510","title":"OCULAR PIGMENT DISPERSION WITH OR WITHOUT GLAUCOMA; OPDG","url":"https://www.omim.org/entry/600510"},{"mim_id":"182889","title":"ZONA PELLUCIDA GLYCOPROTEIN 3; ZP3","url":"https://www.omim.org/entry/182889"},{"mim_id":"105250","title":"AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1","url":"https://www.omim.org/entry/105250"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skin 1","ntpm":548.1}],"url":"https://www.proteinatlas.org/search/GPNMB"},"hgnc":{"alias_symbol":["NMB","HGFIN"],"prev_symbol":[]},"alphafold":{"accession":"Q14956","domains":[{"cath_id":"2.60.40.1930","chopping":"17-123_130-137_156-234","consensus_level":"high","plddt":85.794,"start":17,"end":234},{"cath_id":"2.60.40.10","chopping":"239-324_370-385","consensus_level":"high","plddt":94.1841,"start":239,"end":385},{"cath_id":"2.60.40.10","chopping":"388-486","consensus_level":"high","plddt":89.8399,"start":388,"end":486}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14956","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14956-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14956-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPNMB","jax_strain_url":"https://www.jax.org/strain/search?query=GPNMB"},"sequence":{"accession":"Q14956","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14956.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14956/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14956"}},"corpus_meta":[{"pmid":"17475886","id":"PMC_17475886","title":"Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17475886","citation_count":195,"is_preprint":false},{"pmid":"29519253","id":"PMC_29519253","title":"The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29519253","citation_count":138,"is_preprint":false},{"pmid":"35981040","id":"PMC_35981040","title":"GPNMB confers risk for Parkinson's disease through interaction with α-synuclein.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35981040","citation_count":123,"is_preprint":false},{"pmid":"22891158","id":"PMC_22891158","title":"The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis.","date":"2012","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/22891158","citation_count":113,"is_preprint":false},{"pmid":"32728200","id":"PMC_32728200","title":"The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33.","date":"2020","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32728200","citation_count":106,"is_preprint":false},{"pmid":"35072947","id":"PMC_35072947","title":"GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.","date":"2022","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35072947","citation_count":95,"is_preprint":false},{"pmid":"31701227","id":"PMC_31701227","title":"Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31701227","citation_count":95,"is_preprint":false},{"pmid":"29097143","id":"PMC_29097143","title":"Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.","date":"2017","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/29097143","citation_count":89,"is_preprint":false},{"pmid":"32694855","id":"PMC_32694855","title":"Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance.","date":"2019","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694855","citation_count":84,"is_preprint":false},{"pmid":"31043488","id":"PMC_31043488","title":"TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31043488","citation_count":76,"is_preprint":false},{"pmid":"36054938","id":"PMC_36054938","title":"Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM.","date":"2022","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/36054938","citation_count":75,"is_preprint":false},{"pmid":"26442636","id":"PMC_26442636","title":"Macrophage-Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration Via a CD44-Dependent Mechanism.","date":"2016","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26442636","citation_count":74,"is_preprint":false},{"pmid":"19320736","id":"PMC_19320736","title":"Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion.","date":"2009","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19320736","citation_count":74,"is_preprint":false},{"pmid":"28546082","id":"PMC_28546082","title":"Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.","date":"2017","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28546082","citation_count":73,"is_preprint":false},{"pmid":"26581806","id":"PMC_26581806","title":"Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26581806","citation_count":72,"is_preprint":false},{"pmid":"25772243","id":"PMC_25772243","title":"GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25772243","citation_count":65,"is_preprint":false},{"pmid":"24589892","id":"PMC_24589892","title":"GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24589892","citation_count":64,"is_preprint":false},{"pmid":"18983539","id":"PMC_18983539","title":"Gpnmb is a melanoblast-expressed, MITF-dependent gene.","date":"2008","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/18983539","citation_count":61,"is_preprint":false},{"pmid":"28391543","id":"PMC_28391543","title":"Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease on chromosome 7p15.3.","date":"2017","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28391543","citation_count":61,"is_preprint":false},{"pmid":"22574278","id":"PMC_22574278","title":"Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats.","date":"2012","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/22574278","citation_count":59,"is_preprint":false},{"pmid":"36050467","id":"PMC_36050467","title":"GPNMB: a potent inducer of immunosuppression in cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36050467","citation_count":57,"is_preprint":false},{"pmid":"25010402","id":"PMC_25010402","title":"Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25010402","citation_count":57,"is_preprint":false},{"pmid":"26771826","id":"PMC_26771826","title":"Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26771826","citation_count":54,"is_preprint":false},{"pmid":"19833906","id":"PMC_19833906","title":"Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.","date":"2009","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/19833906","citation_count":47,"is_preprint":false},{"pmid":"22017590","id":"PMC_22017590","title":"Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.","date":"2012","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/22017590","citation_count":46,"is_preprint":false},{"pmid":"20375921","id":"PMC_20375921","title":"GPNMB expression in uveal melanoma: a potential for targeted therapy.","date":"2010","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/20375921","citation_count":44,"is_preprint":false},{"pmid":"25899717","id":"PMC_25899717","title":"Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25899717","citation_count":43,"is_preprint":false},{"pmid":"29336782","id":"PMC_29336782","title":"Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29336782","citation_count":43,"is_preprint":false},{"pmid":"35289033","id":"PMC_35289033","title":"Tumor endothelial cell-induced CD8+ T-cell exhaustion via GPNMB in hepatocellular carcinoma.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35289033","citation_count":42,"is_preprint":false},{"pmid":"27515299","id":"PMC_27515299","title":"MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27515299","citation_count":42,"is_preprint":false},{"pmid":"31218162","id":"PMC_31218162","title":"Microglia express GPNMB in the brains of Alzheimer's disease and Nasu-Hakola disease.","date":"2019","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/31218162","citation_count":40,"is_preprint":false},{"pmid":"12638126","id":"PMC_12638126","title":"mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris.","date":"2002","source":"Brain research. Gene expression patterns","url":"https://pubmed.ncbi.nlm.nih.gov/12638126","citation_count":38,"is_preprint":false},{"pmid":"22912767","id":"PMC_22912767","title":"Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22912767","citation_count":37,"is_preprint":false},{"pmid":"30914799","id":"PMC_30914799","title":"GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30914799","citation_count":35,"is_preprint":false},{"pmid":"34582891","id":"PMC_34582891","title":"GPNMB plays a protective role against obesity-related metabolic disorders by reducing macrophage inflammatory capacity.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34582891","citation_count":35,"is_preprint":false},{"pmid":"26883195","id":"PMC_26883195","title":"Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26883195","citation_count":34,"is_preprint":false},{"pmid":"37661807","id":"PMC_37661807","title":"Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.","date":"2023","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37661807","citation_count":34,"is_preprint":false},{"pmid":"36732560","id":"PMC_36732560","title":"Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36732560","citation_count":33,"is_preprint":false},{"pmid":"34695452","id":"PMC_34695452","title":"GPNMB mitigates Alzheimer's disease and enhances autophagy via suppressing the mTOR signal.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/34695452","citation_count":33,"is_preprint":false},{"pmid":"29620278","id":"PMC_29620278","title":"GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29620278","citation_count":33,"is_preprint":false},{"pmid":"39509324","id":"PMC_39509324","title":"Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39509324","citation_count":32,"is_preprint":false},{"pmid":"27935101","id":"PMC_27935101","title":"GPNMB ameliorates mutant TDP-43-induced motor neuron cell death.","date":"2016","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/27935101","citation_count":32,"is_preprint":false},{"pmid":"32436108","id":"PMC_32436108","title":"Transgenic Overexpression of GPNMB Protects Against MPTP-Induced Neurodegeneration.","date":"2020","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32436108","citation_count":32,"is_preprint":false},{"pmid":"33726823","id":"PMC_33726823","title":"Long non-coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p/GPNMB axis in Parkinson's disease cell model.","date":"2021","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/33726823","citation_count":32,"is_preprint":false},{"pmid":"23884103","id":"PMC_23884103","title":"Endothelin-1 enhances the melanogenesis via MITF-GPNMB pathway.","date":"2013","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/23884103","citation_count":32,"is_preprint":false},{"pmid":"32188902","id":"PMC_32188902","title":"GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32188902","citation_count":31,"is_preprint":false},{"pmid":"33466390","id":"PMC_33466390","title":"Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33466390","citation_count":31,"is_preprint":false},{"pmid":"37806107","id":"PMC_37806107","title":"Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB/CD44 axis in oral squamous cell carcinoma.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37806107","citation_count":30,"is_preprint":false},{"pmid":"17845721","id":"PMC_17845721","title":"Role of human HGFIN/nmb in breast cancer.","date":"2007","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/17845721","citation_count":29,"is_preprint":false},{"pmid":"34608215","id":"PMC_34608215","title":"Anti-inflammatory role of Gpnmb in adipose tissue of mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34608215","citation_count":29,"is_preprint":false},{"pmid":"31822499","id":"PMC_31822499","title":"DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31822499","citation_count":25,"is_preprint":false},{"pmid":"23452376","id":"PMC_23452376","title":"The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB.","date":"2013","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/23452376","citation_count":25,"is_preprint":false},{"pmid":"36737605","id":"PMC_36737605","title":"CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36737605","citation_count":23,"is_preprint":false},{"pmid":"31315839","id":"PMC_31315839","title":"Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex.","date":"2019","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31315839","citation_count":23,"is_preprint":false},{"pmid":"21389974","id":"PMC_21389974","title":"Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21389974","citation_count":22,"is_preprint":false},{"pmid":"21398278","id":"PMC_21398278","title":"Genetic dissection of the Gpnmb network in the eye.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21398278","citation_count":21,"is_preprint":false},{"pmid":"27836549","id":"PMC_27836549","title":"Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na+/K+-ATPase.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27836549","citation_count":21,"is_preprint":false},{"pmid":"35914373","id":"PMC_35914373","title":"miR-532-3p suppresses proliferation and invasion of ovarian cancer cells via GPNMB/HIF-1α/HK2 axis.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35914373","citation_count":20,"is_preprint":false},{"pmid":"33706413","id":"PMC_33706413","title":"N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33706413","citation_count":20,"is_preprint":false},{"pmid":"29290481","id":"PMC_29290481","title":"DLG2, but not TMEM229B, GPNMB, and ITGA8 polymorphism, is associated with Parkinson's disease in a Taiwanese population.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/29290481","citation_count":19,"is_preprint":false},{"pmid":"39455836","id":"PMC_39455836","title":"Bone-marrow macrophage-derived GPNMB protein binds to orphan receptor GPR39 and plays a critical role in cardiac repair.","date":"2024","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39455836","citation_count":18,"is_preprint":false},{"pmid":"38037070","id":"PMC_38037070","title":"Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38037070","citation_count":18,"is_preprint":false},{"pmid":"31498430","id":"PMC_31498430","title":"Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31498430","citation_count":18,"is_preprint":false},{"pmid":"38566120","id":"PMC_38566120","title":"Tumor associated microglia/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38566120","citation_count":17,"is_preprint":false},{"pmid":"38048667","id":"PMC_38048667","title":"PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38048667","citation_count":17,"is_preprint":false},{"pmid":"37919457","id":"PMC_37919457","title":"GPNMB Ameliorates Neuroinflammation Via the Modulation of AMPK/NFκB Signaling Pathway After SAH in Mice.","date":"2023","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37919457","citation_count":17,"is_preprint":false},{"pmid":"30793225","id":"PMC_30793225","title":"Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Ameliorates the Inflammatory Response in Periodontal Disease.","date":"2019","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/30793225","citation_count":17,"is_preprint":false},{"pmid":"15684612","id":"PMC_15684612","title":"Cloning and characterization of the 5' flanking region of the HGFIN gene indicate a cooperative role among p53 and cytokine-mediated transcription factors: relevance to cell cycle regulation.","date":"2005","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15684612","citation_count":16,"is_preprint":false},{"pmid":"36566014","id":"PMC_36566014","title":"A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.","date":"2022","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36566014","citation_count":16,"is_preprint":false},{"pmid":"38219952","id":"PMC_38219952","title":"Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor.","date":"2024","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38219952","citation_count":15,"is_preprint":false},{"pmid":"40381702","id":"PMC_40381702","title":"Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry.","date":"2025","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40381702","citation_count":14,"is_preprint":false},{"pmid":"35110681","id":"PMC_35110681","title":"HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35110681","citation_count":14,"is_preprint":false},{"pmid":"35158847","id":"PMC_35158847","title":"TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35158847","citation_count":14,"is_preprint":false},{"pmid":"28939899","id":"PMC_28939899","title":"GPNMB Induces BiP Expression by Enhancing Splicing of BiP Pre-mRNA during the Endoplasmic Reticulum Stress Response.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28939899","citation_count":14,"is_preprint":false},{"pmid":"33986446","id":"PMC_33986446","title":"Quantitative trait locus mapping identifies the Gpnmb gene as a modifier of mouse macrophage lysosome function.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33986446","citation_count":14,"is_preprint":false},{"pmid":"39992792","id":"PMC_39992792","title":"GPNMB and ATP6V1A interact to mediate microglia phagocytosis of multiple types of pathological particles.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39992792","citation_count":13,"is_preprint":false},{"pmid":"37934943","id":"PMC_37934943","title":"Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","date":"2024","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/37934943","citation_count":13,"is_preprint":false},{"pmid":"34800878","id":"PMC_34800878","title":"GPNMB plays an active role in the M1/M2 balance.","date":"2021","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/34800878","citation_count":13,"is_preprint":false},{"pmid":"34464706","id":"PMC_34464706","title":"Genetic ablation of Gpnmb does not alter synuclein-related pathology.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34464706","citation_count":13,"is_preprint":false},{"pmid":"25663982","id":"PMC_25663982","title":"Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.","date":"2014","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25663982","citation_count":13,"is_preprint":false},{"pmid":"29428978","id":"PMC_29428978","title":"Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.","date":"2018","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/29428978","citation_count":13,"is_preprint":false},{"pmid":"34923085","id":"PMC_34923085","title":"Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker.","date":"2021","source":"Alcohol (Fayetteville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34923085","citation_count":13,"is_preprint":false},{"pmid":"30671053","id":"PMC_30671053","title":"A Host Factor GPNMB Restricts Porcine Circovirus Type 2 (PCV2) Replication and Interacts With PCV2 ORF5 Protein.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30671053","citation_count":13,"is_preprint":false},{"pmid":"34639184","id":"PMC_34639184","title":"GPNMB Extracellular Fragment Protects Melanocytes from Oxidative Stress by Inhibiting AKT Phosphorylation Independent of CD44.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34639184","citation_count":12,"is_preprint":false},{"pmid":"40495034","id":"PMC_40495034","title":"CD206+ macrophages facilitate wound healing through interactions with Gpnmbhi fibroblasts.","date":"2025","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/40495034","citation_count":11,"is_preprint":false},{"pmid":"38009297","id":"PMC_38009297","title":"GPNMB+ Gal-3+ hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38009297","citation_count":11,"is_preprint":false},{"pmid":"34207849","id":"PMC_34207849","title":"Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34207849","citation_count":11,"is_preprint":false},{"pmid":"28689015","id":"PMC_28689015","title":"The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28689015","citation_count":11,"is_preprint":false},{"pmid":"37627399","id":"PMC_37627399","title":"Effects of SLC45A2 and GPNMB on Melanin Deposition Based on Transcriptome Sequencing in Chicken Feather Follicles.","date":"2023","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/37627399","citation_count":11,"is_preprint":false},{"pmid":"29703589","id":"PMC_29703589","title":"Increased GPNMB, phospho-ERK1/2, and MMP-9 in cystic fibrosis in association with reduced arylsulfatase B.","date":"2018","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29703589","citation_count":11,"is_preprint":false},{"pmid":"36875463","id":"PMC_36875463","title":"Serum glycoprotein non-metastatic melanoma protein B (GPNMB) level as a potential biomarker for diabetes mellitus-related cataract: A cross-sectional study.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36875463","citation_count":11,"is_preprint":false},{"pmid":"34280359","id":"PMC_34280359","title":"GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.","date":"2021","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/34280359","citation_count":11,"is_preprint":false},{"pmid":"25843665","id":"PMC_25843665","title":"Aqueous humor phospholipids of DBA/2J and DBA/2J-Gpnmb(+)/SjJ mice.","date":"2015","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/25843665","citation_count":11,"is_preprint":false},{"pmid":"40389121","id":"PMC_40389121","title":"Unlocking diagnostic potential: A retrospective analysis of GPNMB immunohistochemistry in nearly 1000 surgical pathology specimens.","date":"2025","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40389121","citation_count":10,"is_preprint":false},{"pmid":"38140790","id":"PMC_38140790","title":"MDSC suppresses T cell antitumor immunity in CAC via GPNMB in a MyD88-dependent manner.","date":"2023","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38140790","citation_count":10,"is_preprint":false},{"pmid":"39756479","id":"PMC_39756479","title":"Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39756479","citation_count":9,"is_preprint":false},{"pmid":"37956971","id":"PMC_37956971","title":"Glycoprotein Non-Metastatic Protein B (GPNMB): The Missing Link Between Lysosomes and Obesity.","date":"2023","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/37956971","citation_count":9,"is_preprint":false},{"pmid":"34695414","id":"PMC_34695414","title":"Soluble DC-HIL/Gpnmb Modulates T-Lymphocyte Extravasation to Inflamed Skin.","date":"2021","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34695414","citation_count":9,"is_preprint":false},{"pmid":"35809343","id":"PMC_35809343","title":"Role of Gpnmb in atherosclerosis of female mice.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35809343","citation_count":9,"is_preprint":false},{"pmid":"26261527","id":"PMC_26261527","title":"Effects of GPNMB on proliferation and odontoblastic differentiation of human dental pulp cells.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26261527","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52756,"output_tokens":9622,"usd":0.151299,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19802,"output_tokens":5789,"usd":0.121868,"stage2_stop_reason":"end_turn"},"total_usd":0.273167,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"GPNMB translocates from the Golgi apparatus to peripheral vesicular compartments upon macrophage activation with IFN-γ and LPS. Overexpression reduces IL-6, IL-12p40, and NO production in response to LPS, establishing GPNMB as a negative regulator of macrophage inflammatory responses.\",\n      \"method\": \"Epitope-tagged GPNMB overexpression in RAW264.7 cells, fluorescence microscopy co-localization with Golgi marker (coat protein beta), cytokine/NO measurement; DBA/2J mice with inactivating Gpnmb mutation as loss-of-function model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain- and loss-of-function (overexpression + natural mutant mouse), multiple orthogonal readouts (localization, cytokine levels, NO), replicated in cell and in vivo models\",\n      \"pmids\": [\"17475886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GPNMB localizes predominantly to melanosomes (and to a lesser degree lysosomes) in melanocytes, with lesser surface expression. Keratinocytes adhere to immobilized GPNMB in an RGD-dependent manner, establishing GPNMB as a melanosome-associated glycoprotein mediating melanocyte–keratinocyte adhesion via its RGD motif.\",\n      \"method\": \"Immunofluorescence, subcellular fractionation, newly developed monoclonal antibody for surface staining, RGD-dependent adhesion assay with PAM212 keratinocytes\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence (adhesion assay), RGD-blocking control, multiple cell types tested\",\n      \"pmids\": [\"19320736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"EGFP-tagged GPNMB localizes to vesicular, endosomal-like structures in non-pigmented COS7 and HEK293 cells, consistent with an endosomal/melanosomal sorting signal (ExxPLL di-leucine motif) in its cytoplasmic domain.\",\n      \"method\": \"EGFP-GPNMB transfection in COS7 and HEK293 cells with fluorescence microscopy; sequence analysis identifying ExxPLL motif\",\n      \"journal\": \"Brain research. Gene expression patterns\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization in two cell lines, but no functional mutagenesis of the sorting motif in this study\",\n      \"pmids\": [\"12638126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gpnmb expression in melanoblasts is directly regulated by the transcription factor MITF. A conserved element (GPNMB-MCS3) containing two MITF consensus binding sites drives Gpnmb expression in melanoblasts in vivo; deletion of the 5'-most MITF site dramatically reduces enhancer activity.\",\n      \"method\": \"Luciferase reporter assay in melanocytes, in vivo enhancer-driven expression in melanoblasts, MITF mutant mouse analysis, whole-genome annotation of MITF binding sites\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reporter assay with deletion mutagenesis plus in vivo validation in mutant animals; multiple orthogonal approaches\",\n      \"pmids\": [\"18983539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Silencing GPNMB by siRNA in PIG1 melanocytes sharply reduces the total number of melanosomes and decreases expression of melanosome structural proteins (tyrosinase, TRP1, Pmel17/gp100, OA1), demonstrating that GPNMB is required for melanosome formation in a MITF-independent fashion.\",\n      \"method\": \"siRNA knockdown of GPNMB in PIG1 melanocytes; transmission electron microscopy, qPCR, Western blot, immunofluorescence\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with TEM as direct ultrastructural readout plus multiple molecular markers; single lab but ≥2 orthogonal methods\",\n      \"pmids\": [\"22912767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The PKD domain of GPNMB lacks the sorting function present in the homologous PKD domain of PMEL. The difference is attributed to extensive N-glycosylation of the GPNMB PKD domain, which nullifies its sorting function. As a result, GPNMB localizes to compartments distinct from PMEL-containing multivesicular premelanosomes and is absent from amyloid fibrils.\",\n      \"method\": \"Domain-swapping experiments between PMEL and GPNMB in melanocytes and HeLa cells; fluorescence microscopy; glycosylation analysis\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — domain-swap mutagenesis plus localization in two cell types; mechanistic attribution to N-glycosylation of PKD domain\",\n      \"pmids\": [\"23452376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ET-1 induces melanogenesis via a MITF-regulated GPNMB pathway: ET-1 upregulates MITF, which in turn increases GPNMB expression; GPNMB silencing abolishes ET-1-induced melanosome formation and melanin synthesis, and MITF siRNA suppresses GPNMB expression and prevents ET-1-mediated pigmentation.\",\n      \"method\": \"siRNA knockdown of GPNMB and MITF in melanocytes, melanin quantification, melanosome counting, Western blot\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistatic placement of MITF upstream of GPNMB by dual siRNA knockdown; single lab\",\n      \"pmids\": [\"23884103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPNMB engages α5β1 integrin through its RGD motif to promote breast cancer cell adhesion to fibronectin and activate Src and FAK signaling. Both the RGD motif and cytoplasmic tail are required for primary tumor growth, but only the RGD motif is required for lung metastasis. GPNMB also increases NRP-1 expression to potentiate VEGF signaling required for tumor growth but not metastasis.\",\n      \"method\": \"RGD-motif mutagenesis, cytoplasmic tail deletion, integrin co-immunoprecipitation, in vivo breast cancer mouse models, RNAseq correlation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-directed mutagenesis of RGD and cytoplasmic tail with in vitro and in vivo functional rescue; Co-IP; multiple orthogonal approaches\",\n      \"pmids\": [\"25772243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"M2 macrophage-secreted GPNMB promotes MSC survival, proliferation, and migration via CD44 receptor, activating ERK and AKT signaling pathways in MSCs. Loss-of-function and rescue experiments confirmed CD44-dependence.\",\n      \"method\": \"Loss-of-function (GPNMB knockdown) and rescue studies in macrophage–MSC co-culture system; ERK/AKT phosphorylation assays; CD44 blocking\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function plus rescue, downstream signaling readout; single lab\",\n      \"pmids\": [\"26442636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB transgenic overexpression in mice enhances bone formation, increases osteoblast numbers and bone formation rates, and is associated with upregulated TGF-β1 and TGF-β receptor I/II expression in osteoblasts, indicating an osteoinductive effect.\",\n      \"method\": \"Transgenic mouse (CMV-promoter GPNMB overexpression): micro-CT, histomorphometry, biomechanical testing, ELISA, qRT-PCR\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain-of-function with multiple structural and molecular readouts; single lab\",\n      \"pmids\": [\"25899717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPNMB interacts with Na+/K+-ATPase α subunits to activate PI3K/Akt and MEK/ERK pathways in glioblastoma. Ouabain (a Na+/K+-ATPase inhibitor) suppresses GPNMB-driven glioma growth and blocks GPNMB-induced glioma cell migration. This interaction was confirmed in both a murine glioma model and human glioblastoma tumors.\",\n      \"method\": \"Co-immunoprecipitation (GPNMB–Na+/K+-ATPase), transgenic GPNMB mice with in vivo glioma implantation, ouabain pharmacological inhibition, migration assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vivo functional validation with pharmacological inhibition; single lab\",\n      \"pmids\": [\"27836549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Recombinant GPNMB protects motor neurons from mutant TDP-43-induced cell death by activating ERK1/2 and Akt signaling pathways. GPNMB co-localizes with TDP-43 aggregates in neurons (but not astrocytes or microglia) of ALS patient spinal cord.\",\n      \"method\": \"Recombinant GPNMB treatment of NSC34 motor neuron cells transfected with mutant TDP-43; Western blot for p-ERK1/2, p-Akt; immunohistochemistry of ALS patient spinal cord\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant protein rescue experiment with defined signaling readout; single lab\",\n      \"pmids\": [\"27935101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPNMB neuroprotection during ischemia-reperfusion involves activation of ERK1/2 and Akt. Transgenic GPNMB overexpression significantly reduces infarct volume and increases phospho-ERK1/2 and phospho-Akt. Recombinant extracellular GPNMB fragment alone is sufficient to reduce infarction, mapping the neuroprotective activity to the extracellular domain.\",\n      \"method\": \"GPNMB transgenic mice with MCAO model; recombinant GPNMB treatment; Western blot for p-ERK1/2 and p-Akt; infarct volume measurement\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression plus recombinant protein rescue, signaling pathway readout; single lab\",\n      \"pmids\": [\"25010402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPNMB induces BiP (GRP78) expression during ER stress by translocating to the nucleus and promoting BiP pre-mRNA splicing through a mechanism independent of the three canonical UPR transducers (IRE1, PERK, ATF6). GPNMB transgenic mice exhibit elevated BiP and reduced infarct size after cerebral artery occlusion.\",\n      \"method\": \"Thapsigargin-induced ER stress, nuclear fractionation showing GPNMB nuclear translocation, BiP mRNA/pre-mRNA splicing assay, IRE1/PERK/ATF6 pathway inhibitor controls, GPNMB transgenic mouse MCAO model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — nuclear translocation by fractionation, mRNA splicing assay, pathway exclusion controls, in vivo validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"28939899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The anti-inflammatory effects of soluble GPNMB on astrocytes are mediated through the CD44 receptor. Recombinant GPNMB attenuates cytokine-induced iNOS, NO, ROS, and IL-6 in astrocytes; this effect is lost in CD44 knockout astrocytes.\",\n      \"method\": \"Recombinant GPNMB treatment of wild-type and CD44-KO primary mouse astrocytes; measurement of iNOS, NO, ROS, IL-6\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO of receptor (CD44-KO astrocytes) as clean loss-of-function; multiple inflammatory readouts; confirms CD44 as functional receptor\",\n      \"pmids\": [\"29519253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Soluble macrophage-derived GPNMB activates cancer cells to express IL-33 and its receptor IL-1RL1 through the CD44 receptor, driving cancer stem cell formation (spheroids), prolonged survival, and metastatic phenotype. IL-33 binding to IL-1RL1 is sufficient to induce tumor spheroid formation.\",\n      \"method\": \"Mouse tumor models with Gpnmb-mutant DBA/2J mice, GPNMB receptor blocking with anti-CD44, IL-33/IL-1RL1 functional reconstitution, spheroid formation assay\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model, receptor blocking, reconstitution with IL-33; multiple orthogonal approaches establishing GPNMB→CD44→IL-33 axis\",\n      \"pmids\": [\"32728200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gpnmb is a liver-secreted factor that stimulates lipogenesis in white adipose tissue (WAT). Hepatic SREBP pathway inhibition increases Gpnmb transcription and promotes its processing to a secreted form. Liver-specific knockdown or neutralizing antibody against Gpnmb improves metabolic parameters and promotes WAT beiging.\",\n      \"method\": \"Liver-specific Gpnmb knockdown, neutralizing antibody treatment, Gpnmb transgenic mice, SREBP pathway manipulation, metabolic phenotyping (weight, insulin sensitivity)\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — liver-specific KD, neutralizing antibody, transgenic overexpression, multiple metabolic readouts; replicated across multiple genetic and pharmacological approaches\",\n      \"pmids\": [\"32694855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPNMB is a direct transcriptional target of TFE3 fusion proteins. In a TFE3-RCC mouse model, GPNMB expression was elevated in TFE3-driven renal tumors, and TFE3 fusion was confirmed to directly transactivate GPNMB.\",\n      \"method\": \"PRCC-TFE3 transgenic mouse model; GPNMB IHC; confirmed TFE3 direct transcriptional target by reporter/functional analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic model with transcriptional target confirmation; single lab\",\n      \"pmids\": [\"31043488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPNMB upregulation is downstream of TSC2 loss and is dependent on MiT/TFE transcription factors and mTORC1 activity. In AML/kidney cell lines with CRISPR-mediated TSC2 loss, GPNMB is upregulated in a TFE3/TFEB- and mTORC1-dependent fashion.\",\n      \"method\": \"CRISPR-Cas9 TSC2/TFE3/TFEB knockout in AML and kidney cell lines; GPNMB immunohistochemistry; Tsc2+/- mouse model\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR genetic dissection in multiple cell lines plus in vivo mouse model, pathway placed downstream of TSC2/mTORC1/MiT-TFE axis\",\n      \"pmids\": [\"35072947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPNMB regulates EGFR activation and downstream STAT3 signaling in NSCLC. N-glycosylation at Asn134 of GPNMB is essential for its binding to the C-terminus of mutated EGFR and for ligand-independent EGFR phosphorylation at Y845. Depleting N134 glycosylation abolishes GPNMB–EGFR binding and downstream signaling.\",\n      \"method\": \"Membrane proteomics, Co-IP of GPNMB–EGFR, N134A glycosylation mutant, phospho-EGFR (Y845) and STAT3 assays, in vivo metastasis model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of glycosylation site, Co-IP, in vitro signaling assay, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"33706413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Takayasu arteritis risk allele in IL6 (rs2069837 A) represses GPNMB expression ~520 kb away by recruiting a MEF2-HDAC repressive complex through long-range intrachromatin looping. HDAC inhibition reverses GPNMB suppression in macrophages from AA genotype individuals.\",\n      \"method\": \"EMSA, DNA affinity precipitation + mass spectrometry, luciferase reporter assay, chromosome conformation capture (3C), primary macrophage experiments with HDAC inhibition\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — 3C for chromatin looping, EMSA and affinity pulldown for protein-DNA interaction, reporter assay with deletion, pharmacological reversal; multiple orthogonal Tier 1-2 methods\",\n      \"pmids\": [\"31315839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB reduces macrophage inflammatory capacity by inhibiting NF-κB signaling largely through binding to CD44. In GPNMB-KO mice, macrophages produce more inflammatory cytokines; supplementation with recombinant soluble GPNMB extracellular domain abolishes this difference. Macrophage depletion abrogates the worsened metabolic phenotype of GPNMB-KO mice.\",\n      \"method\": \"GPNMB-KO mouse (CRISPR), HFD metabolic phenotyping, macrophage isolation and cytokine measurement, recombinant GPNMB rescue, clodronate liposome macrophage depletion, NF-κB signaling assay, CD44 blocking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with multiple orthogonal approaches: recombinant rescue, macrophage depletion, CD44 blocking, NF-κB readout\",\n      \"pmids\": [\"34582891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Gpnmb is required for normal macrophage lysosome function. Gpnmb is the causal gene at the strongest QTL for lysosome function (Mlfm1). siRNA knockdown of Gpnmb in AKR/J macrophages and CRISPR-Cas9 deletion in RAW264.7 cells both decrease lysosome function; restoration of wild-type Gpnmb in a DBA/2 substrain recovers lysosome function.\",\n      \"method\": \"QTL mapping, siRNA knockdown, CRISPR-Cas9 knockout in RAW264.7 cells, dual-labeled lysosome function assay, DBA/2J-Gpnmb+/SjJ substrain comparison\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — three independent loss-of-function approaches (siRNA, CRISPR, natural null mutation) plus genetic rescue substrain; converging on lysosome function\",\n      \"pmids\": [\"33986446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB reduces Aβ deposition and improves Alzheimer's-like behaviors in APP/PS1 mice by enhancing autophagy through suppression of mTOR signaling. Autophagy inhibitor 3-MA abolishes the beneficial effect of GPNMB on Aβ clearance, placing GPNMB upstream of mTOR-dependent autophagy.\",\n      \"method\": \"GPNMB overexpression in APP/PS1 mice; TEM and immunofluorescence for autophagy (beclin-1); 3-MA autophagy inhibition; Aβ quantification; mTOR pathway Western blot\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function plus pharmacological pathway blockade; single lab\",\n      \"pmids\": [\"34695452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPNMB co-immunoprecipitates and co-localizes with α-synuclein (aSyn) in cells. In iPSC-derived neurons, loss of GPNMB results in loss of ability to internalize aSyn fibrils and develop aSyn pathology.\",\n      \"method\": \"Co-immunoprecipitation, co-localization immunofluorescence, GPNMB loss-of-function in iPSC-derived neurons with aSyn fibril uptake assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus genetic loss-of-function in physiologically relevant iPSC-derived neurons with functional readout (fibril internalization)\",\n      \"pmids\": [\"35981040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPNMB binds to integrin αVβ1 receptor on adventitial fibroblasts and activates downstream Akt and Erk signaling, promoting extracellular matrix production. This was established by Co-IP, siRNA, and inhibitor intervention studies in Takayasu arteritis vascular fibrosis.\",\n      \"method\": \"Co-IP assay (GPNMB–integrin αVβ1), siRNA knockdown of integrin αVβ1, pharmacological pathway inhibitors (Akt/Erk), ECM gene expression assays in adventitial fibroblasts\",\n      \"journal\": \"Translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus siRNA and inhibitor validation; single lab\",\n      \"pmids\": [\"36566014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HSP90 inhibition increases GPNMB cell-surface localization by inducing lysosomal dispersion toward the cell periphery and lysosome–plasma membrane fusion, delivering GPNMB to the cell surface. This is distinct from transcriptional induction and requires lysosomal repositioning.\",\n      \"method\": \"FACS-based genetic screen, live-cell imaging of lysosomal positioning, lysosome–plasma membrane fusion assay, GPNMB surface FACS after HSP90 inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic screen plus mechanistic imaging of lysosomal dispersion; multiple orthogonal methods establishing lysosome-to-surface trafficking mechanism\",\n      \"pmids\": [\"35110681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-derived GPNMB is trapped by fibrotic ECM and activates resident fibroblasts via the CD44/Serpinb2 pathway, driving pulmonary fibrosis progression. Neutralizing antibodies against GPNMB or macrophage depletion attenuates fibroblast activation in fibrotic ECM.\",\n      \"method\": \"Silica-instilled mouse PF model, fibroblast activation assay with fibrotic ECM, GPNMB-neutralizing antibody treatment, macrophage depletion, Western blot for CD44/Serpinb2\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blockade and macrophage depletion with pathway readout; single lab\",\n      \"pmids\": [\"36732560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Lactic acid-induced M2-like macrophage-derived GPNMB promotes OSCC cell migration, invasion, and EMT by binding to the CD44 receptor and activating the PI3K/AKT/mTOR signaling cascade. CD44 silencing abrogates these tumor-promoting effects.\",\n      \"method\": \"Co-culture system, GPNMB-CD44 binding assay, CD44 siRNA knockdown, PI3K/AKT/mTOR inhibition, migration/invasion assays\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor knockdown with pathway readout; single lab\",\n      \"pmids\": [\"37806107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Bone-marrow-derived macrophages are the primary source of GPNMB in injured hearts after myocardial infarction. GPNMB deficiency leads to increased mortality, cardiac rupture, and left ventricular dysfunction. GPR39 is identified as a receptor for circulating GPNMB; GPR39 absence negates the beneficial cardiac effects of GPNMB. Single-cell transcriptomics showed GPNMB enhances cardiomyocyte contraction and reduces fibroblast activation.\",\n      \"method\": \"Lineage tracing, bone-marrow transplantation, GPNMB loss-of-function (genetic), viral GPNMB delivery for gain-of-function, single-cell RNA sequencing, GPR39 KO rescue experiment\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO, KO rescue with GPR39-KO, viral delivery), lineage tracing, scRNA-seq; multiple orthogonal approaches identifying GPR39 as functional receptor\",\n      \"pmids\": [\"39455836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GPNMB interacts with lysosomal vacuolar-type proton ATPase catalytic subunit A (ATP6V1A) to mediate microglial phagocytosis of pathological particles including neuronal debris and β-amyloid. GPNMB is internalized into cells, wraps engulfed particles, and presents them to lysosomes via ATP6V1A interaction. Activating ATP6V1A rescues GPNMB-deficiency-caused phagocytosis impairment.\",\n      \"method\": \"Co-immunoprecipitation (GPNMB–ATP6V1A), GPNMB genetic ablation, phagocytosis assay (engulfment and degradation), ATP6V1A activation rescue experiment, live-cell imaging of GPNMB trafficking\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifying interactor, KO phenotype, pharmacological rescue of phagocytosis; multiple orthogonal approaches\",\n      \"pmids\": [\"39992792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PPARγ directly targets GPNMB to promote oligodendrocyte precursor cell (OPC) differentiation and CNS remyelination. PPARγ agonists increase GPNMB expression and enhance remyelination; oligodendrocyte-specific PPARγ KO decreases OPC maturation. GPNMB itself drives OPC-to-oligodendrocyte differentiation and promotes myelinogenesis.\",\n      \"method\": \"PPARγ oligodendrocyte-specific KO, PPARγ agonist treatment, ChIP/transcriptional target validation of GPNMB, cuprizone and lysophosphatidylcholine demyelination models, GPNMB overexpression/knockdown in OPCs\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-specific KO, direct transcriptional target confirmation, two independent demyelination models, GPNMB gain/loss-of-function; multiple orthogonal methods\",\n      \"pmids\": [\"39756479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Glycosylation of GPNMB is inhibited by interaction with mutant SOD1(G93A) in NSC34 cells, increasing motor neuron vulnerability. Extracellular fragments of GPNMB secreted from activated astrocytes attenuate SOD1(G93A) neurotoxicity in neural cells, establishing a neuroprotective paracrine role.\",\n      \"method\": \"Co-culture of NSC34 cells and astrocytes, glycosylation assay, SOD1(G93A) interaction, neurotoxicity rescue with extracellular GPNMB fragments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction and functional rescue; single lab, single study\",\n      \"pmids\": [\"22891158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Soluble Gpnmb in NAFLD interacts with calnexin in hepatic macrophages and stellate cells, and this interaction is associated with reduced oxidative stress. Gpnmb transgenic overexpression ameliorates fat accumulation and liver fibrosis in diet-induced obesity.\",\n      \"method\": \"Gpnmb transgenic mice (aP2-driven), co-immunoprecipitation (Gpnmb–calnexin), oxidative stress markers, histological analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying calnexin interaction plus in vivo transgenic model; single lab\",\n      \"pmids\": [\"26581806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"p53 cooperates with cytokine-mediated transcription factors to regulate HGFIN/GPNMB expression. EMSA demonstrated that p53 can interact with HGFIN promoter fragments containing p53 consensus sites. Reporter gene analyses showed p53 level correlates with HGFIN promoter activity; the untranslated exon 1 acts as a negative regulator of upstream enhancing effects.\",\n      \"method\": \"EMSA with Cy3-labeled PCR fragments, luciferase reporter assays in cells with varying p53 levels, modified cell lines with reduced cytokine production\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and reporter assay with multiple cell lines; single lab, focused on promoter regulation\",\n      \"pmids\": [\"15684612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Soluble DC-HIL (GPNMB) binds syndecan-4 on both T cells and endothelial cells. In an allergic contact dermatitis model, sDC-HIL downregulates the allergic reaction by reducing transendothelial T-cell migration (but not neutrophil or mast cell migration). This requires syndecan-4 expression on both endothelial cells and T cells.\",\n      \"method\": \"Allergic contact dermatitis mouse model, intravital microscopy, syndecan-4-deficient mice, intravenous sDC-HIL infusion, flow cytometry of immune cell infiltration\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO of syndecan-4 in both cell types establishes receptor requirement; intravital microscopy confirms cell-specific migration block; multiple orthogonal methods\",\n      \"pmids\": [\"34695414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPNMB extracellular soluble fragment protects melanocytes from oxidative stress-induced cytotoxicity and melanogenesis impairment through suppression of AKT phosphorylation, independently of CD44 (CD44 knockdown did not affect the protective effect).\",\n      \"method\": \"siRNA knockdown of CD44, recombinant soluble GPNMB treatment, AKT/ERK/p38/JNK phosphorylation assays, melanocyte viability assay\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor knockdown plus signaling assays establishing CD44-independent, AKT-dependent mechanism; single lab\",\n      \"pmids\": [\"34639184\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPNMB is a type I transmembrane glycoprotein that functions as a context-dependent signaling molecule: it localizes to melanosomes/lysosomes via a cytoplasmic ExxPLL sorting motif and is required for melanosome biogenesis; its extracellular RGD domain mediates cell adhesion through integrins (α5β1, αVβ1) and activates Src/FAK and Akt/Erk signaling; its soluble ectodomain (shed by ADAM10) signals through CD44 to inhibit NF-κB-mediated inflammation and through GPR39 to support cardiac repair; it interacts with α-synuclein and is required for aSyn fibril internalization; it promotes lysosomal function by interacting with ATP6V1A to facilitate phagocytic degradation; it translocates to the nucleus during ER stress to enhance BiP pre-mRNA splicing; and its expression is transcriptionally regulated by MITF (in melanocytes), TFE3/TFEB (downstream of TSC/mTOR), PPARγ (in oligodendrocytes), and p53/cytokine-mediated transcription factors.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GPNMB is a type I transmembrane glycoprotein that operates both as a melanosomal/lysosomal sorting cargo and, after ectodomain shedding, as a secreted signaling ligand coordinating tissue repair, anti-inflammatory responses, and protein/particle degradation [#1, #16, #21]. In melanocytes it localizes predominantly to melanosomes via a cytoplasmic ExxPLL di-leucine sorting motif and is required for melanosome biogenesis, acting downstream of MITF, whose direct binding to a conserved enhancer drives GPNMB transcription [#2, #3, #4]. Distinct N-glycosylation of its PKD domain diverts GPNMB away from the PMEL amyloidogenic compartment, and its surface delivery can be controlled by lysosome-to-plasma-membrane repositioning [#5, #26]. The extracellular domain mediates adhesion and signaling through multiple receptors: an RGD motif engages integrins (α5β1, αVβ1) to activate Src/FAK and Akt/Erk and drive tumor growth and ECM production, while the shed soluble ectodomain signals through CD44 to inhibit NF-κB-dependent inflammation in macrophages and astrocytes and, through GPR39, to support cardiac repair after myocardial infarction [#7, #14, #21, #25, #29]. Beyond cell-surface signaling, GPNMB promotes lysosomal and degradative function by interacting with the vacuolar ATPase subunit ATP6V1A to drive microglial phagocytosis of neuronal debris and β-amyloid, and it is required for internalization of α-synuclein fibrils through direct binding to α-synuclein [#22, #24, #30]. During ER stress it translocates to the nucleus to enhance BiP pre-mRNA splicing independently of the canonical UPR transducers [#13]. Its expression is integrated into multiple transcriptional programs, including MITF, the MiT/TFE factors TFE3/TFEB downstream of TSC2/mTORC1, PPARγ during oligodendrocyte differentiation, and p53/cytokine-driven regulation [#3, #18, #31, #34].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that GPNMB carries an intrinsic endosomal/melanosomal sorting determinant, framing it as a vesicular trafficking cargo rather than a simple surface protein.\",\n      \"evidence\": \"EGFP-GPNMB localization in COS7 and HEK293 cells with identification of an ExxPLL di-leucine motif\",\n      \"pmids\": [\"12638126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional mutagenesis of the sorting motif in this study\", \"Sorting machinery (adaptors) not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified MITF as a direct upstream transcriptional driver of GPNMB in the melanocyte lineage, placing GPNMB within the pigmentation gene regulatory network.\",\n      \"evidence\": \"Luciferase reporter with MITF-site deletion plus in vivo enhancer activity and MITF mutant mouse analysis\",\n      \"pmids\": [\"18983539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address MITF-independent expression in other tissues\", \"Did not link transcription to melanosome phenotype directly\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed GPNMB is a melanosome-associated glycoprotein whose RGD motif mediates melanocyte-keratinocyte adhesion, giving the extracellular domain a defined adhesive function.\",\n      \"evidence\": \"Immunofluorescence, subcellular fractionation, and RGD-dependent keratinocyte adhesion assay\",\n      \"pmids\": [\"19320736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adhesion receptor on keratinocytes not identified in this study\", \"Functional significance for melanosome transfer not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated GPNMB is required for melanosome biogenesis, establishing a cell-intrinsic structural/biogenic role distinct from its signaling functions.\",\n      \"evidence\": \"siRNA knockdown in PIG1 melanocytes with TEM, qPCR, and Western blot for melanosome markers\",\n      \"pmids\": [\"22912767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GPNMB supports melanosome formation not resolved\", \"Whether effect is via sorting of structural proteins unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"First established GPNMB as a negative regulator of macrophage inflammation, reframing it from a structural pigment-cell protein to an immunomodulator.\",\n      \"evidence\": \"Overexpression in RAW264.7 cells with cytokine/NO readouts plus DBA/2J Gpnmb-mutant mouse\",\n      \"pmids\": [\"17475886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating anti-inflammatory effect not identified\", \"Mechanism linking localization shift to cytokine suppression unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Explained why GPNMB diverges from its PMEL paralog by attributing loss of PKD-domain sorting to N-glycosylation, separating GPNMB from the amyloidogenic premelanosome compartment.\",\n      \"evidence\": \"PMEL/GPNMB domain-swap mutagenesis with glycosylation analysis and localization in melanocytes and HeLa cells\",\n      \"pmids\": [\"23452376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of compartment segregation not tested\", \"ET-1/MITF axis (idx 6) link to sorting not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped tumor-promoting functions to distinct GPNMB domains, showing RGD-integrin engagement drives metastasis while both RGD and cytoplasmic tail support primary growth via Src/FAK.\",\n      \"evidence\": \"RGD and cytoplasmic-tail mutagenesis, integrin Co-IP, and in vivo breast cancer mouse models\",\n      \"pmids\": [\"25772243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic tail downstream effectors not defined\", \"How NRP-1 upregulation occurs mechanistically unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined CD44 as a functional receptor for soluble GPNMB driving ERK/AKT-mediated survival and migration, and extended GPNMB signaling to additional receptors (Na+/K+-ATPase) and tissues (bone).\",\n      \"evidence\": \"Macrophage-MSC co-culture with CD44 blocking and rescue; Co-IP with Na+/K+-ATPase in glioma; transgenic bone-formation phenotyping\",\n      \"pmids\": [\"26442636\", \"27836549\", \"25899717\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether single ligand engages multiple receptors simultaneously unknown\", \"Stoichiometry and affinity of receptor interactions not measured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Uncovered a non-canonical nuclear function in which GPNMB enhances BiP pre-mRNA splicing during ER stress, independent of IRE1/PERK/ATF6, linking GPNMB to UPR and neuroprotection.\",\n      \"evidence\": \"Thapsigargin ER stress with nuclear fractionation, BiP splicing assay, UPR-pathway inhibitor controls, and transgenic MCAO mice\",\n      \"pmids\": [\"28939899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a transmembrane protein reaches the nucleus mechanistically unresolved\", \"Splicing machinery partners not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed CD44 as the receptor for the anti-inflammatory action of soluble GPNMB using clean genetic loss-of-function, generalizing this axis to CNS glia.\",\n      \"evidence\": \"Recombinant GPNMB on wild-type vs CD44-KO astrocytes with iNOS/NO/ROS/IL-6 readouts\",\n      \"pmids\": [\"29519253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NF-κB step not yet directly tied in this study\", \"Co-receptors of CD44 not examined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Integrated GPNMB into multiple transcriptional and metabolic programs—MiT/TFE downstream of TSC2/mTORC1, TFE3 fusions in RCC, hepatic SREBP-controlled secretion driving adipose lipogenesis, and EGFR-glycosylation-dependent signaling in NSCLC.\",\n      \"evidence\": \"CRISPR TSC2/TFE3/TFEB knockouts; PRCC-TFE3 transgenic model; liver-specific knockdown/neutralizing antibody with metabolic phenotyping; N134A glycosylation mutant with EGFR Co-IP\",\n      \"pmids\": [\"35072947\", \"31043488\", \"32694855\", \"33706413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific balance between secreted ligand and surface signaling unclear\", \"Whether EGFR and integrin functions share a common pool of GPNMB unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed long-range chromatin regulation of GPNMB, with a Takayasu-associated IL6 variant recruiting a MEF2-HDAC repressive complex to suppress GPNMB ~520 kb away.\",\n      \"evidence\": \"EMSA, DNA affinity precipitation/MS, luciferase reporters, 3C chromatin looping, and HDAC inhibition in primary macrophages\",\n      \"pmids\": [\"31315839\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of macrophage GPNMB loss in disease not fully traced here\", \"Other distal regulatory elements not catalogued\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established GPNMB as a determinant of macrophage lysosome function and confirmed CD44-dependent suppression of NF-κB inflammation, tying a degradative-organelle role to metabolic and immune phenotypes.\",\n      \"evidence\": \"QTL mapping with siRNA, CRISPR-KO, and natural-null rescue for lysosome function; GPNMB-KO mouse HFD model with recombinant rescue, macrophage depletion, CD44 blocking, and NF-κB readout\",\n      \"pmids\": [\"33986446\", \"34582891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between GPNMB and lysosome machinery not yet defined in these studies\", \"Relationship between surface signaling and intracellular lysosomal role unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified GPNMB as a direct α-synuclein interactor required for fibril internalization and as an integrin αVβ1 ligand driving fibrosis, expanding its roles into neurodegeneration uptake and pathological ECM production.\",\n      \"evidence\": \"Co-IP and co-localization with α-synuclein plus iPSC-neuron loss-of-function fibril-uptake assay; Co-IP, siRNA, and inhibitor studies for αVβ1 in fibroblasts\",\n      \"pmids\": [\"35981040\", \"36566014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GPNMB acts as a fibril receptor or co-factor not fully defined\", \"Mechanism coupling fibril binding to internalization route unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified GPR39 as a receptor for circulating GPNMB mediating cardiac repair, and resolved the cell-of-origin (bone-marrow-derived macrophages) for injury-induced GPNMB.\",\n      \"evidence\": \"Lineage tracing, bone-marrow transplantation, genetic loss-of-function, viral gain-of-function, scRNA-seq, and GPR39-KO rescue in myocardial infarction\",\n      \"pmids\": [\"39455836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GPR39 vs CD44 receptor selection by tissue not explained\", \"Direct GPNMB-GPR39 binding interface not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a mechanistic link between GPNMB and the degradative apparatus, showing GPNMB binds the V-ATPase subunit ATP6V1A to present engulfed particles to lysosomes during microglial phagocytosis, and connected GPNMB to PPARγ-driven remyelination.\",\n      \"evidence\": \"Co-IP of GPNMB-ATP6V1A with KO phagocytosis assay and ATP6V1A activation rescue; PPARγ oligodendrocyte-specific KO, ChIP target validation, and demyelination models\",\n      \"pmids\": [\"39992792\", \"39756479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GPNMB couples particle wrapping to V-ATPase function structurally unknown\", \"Whether ATP6V1A interaction underlies earlier lysosome-function QTL effect not directly tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how GPNMB partitions among its diverse receptors (CD44, GPR39, integrins α5β1/αVβ1, syndecan-4) and intracellular partners (ATP6V1A, α-synuclein, calnexin) in a tissue- and context-specific manner, and what governs the choice between membrane signaling, ectodomain shedding, and nuclear translocation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying model linking receptor selection to ligand processing\", \"Structural basis of multi-receptor engagement undefined\", \"Relative in vivo contribution of each axis to physiology not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [14, 21, 29]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 14, 25, 29]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1, 22, 26, 30]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 7, 26]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [12, 14, 16, 21]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 14, 25, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 14, 21]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [23, 30]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 33]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 18, 20, 31, 34]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [4, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD44\", \"GPR39\", \"ITGAV\", \"ITGB1\", \"ATP6V1A\", \"SNCA\", \"EGFR\", \"SDC4\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}